Skip to main content
. 2016 Jan 15;8(1):17. doi: 10.3390/cancers8010017

Figure 2.

Figure 2

Immune checkpoints in melanoma therapy. Blockade of CTLA-4 or PD-1/PD-L1 results in the activation of T cells with specificity for cancer cells.